NOVONESIS A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 384.8 DKK | +0.04% |
|
-0.28% | +3.99% |
| Apr. 08 | Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023 | CI |
| Mar. 26 | China to speed up 'new productive forces', vice president says | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.65 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.99% | 25.69B | B+ | ||
| -25.05% | 3.32B | - | C+ | |
| -23.44% | 547M | - | ||
| -26.34% | 384M | - | - | |
| -81.65% | 216M | - | - | |
| -11.32% | 114M | - | - | |
| -16.67% | 50.23M | D |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NSIS B Stock
- Ratings Novonesis A/S
